Welcome to AZ MedX

AstraZeneca’s Respiratory & Immunology medical resource centre for healthcare professionals

Discover the latest advances and approaches in asthma, COPD and more

This site is intended for the use of Healthcare Professionals only. By clicking the link below you declare and confirm:

If you are not a Healthcare Professional, please follow this link for information on global patient resources.

SABA Reliever Over-Reliance

Many people with asthma tend to over-rely on their short-acting β2-agonist (SABA) inhaler [1]. Although they provide quick relief of symptoms, using SABA inhalers three or more times per week is associated with poor asthma control and can increase the risk of exacerbations and mortality [2,3].

The Blue Reliever Reliance Test – featuring a simple, five-item, evidence-based questionnaire – can support you to assess SABA over-reliance with your patients and explore their asthma management needs.

Try the blue reliever reliance test for yourself

Are your asthma patients over-reliant on their SABA inhalers?


[1] Janson C et al. Adv Ther. 2020;37:1124–1135.

[2] Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2021 GINA Report. Available from: https://ginasthma.org/reports/.

[3] Nwaru BI et al. Eur Respir J. 2020;55:1901872.

You are now leaving: http://azmedx.com/

By following this link you will be leaving the AZ MedX website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to AZ MedX